Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT -
Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR+/HER2- metastatic breast cancer
Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib - Ajay Dhakal, Roby Antony Thomas, Ellis G Levine, Adam Brufsky, Kazuaki Takabe, Matthew G Hanna, Kristopher Attwood,
Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2 – OncoPrescribe
Afinitor 10mg tablets - Summary of Product Characteristics (SmPC) - (emc)
Cancers | Free Full-Text | Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 - ScienceDirect
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer | NEJM
Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors - ScienceDirect
Kaplan-Meier Analysis of Progression-Free Survival (PFS) in Patients... | Download Scientific Diagram
Everolimus Sandoz 10 mg Tablets - Summary of Product Characteristics (SmPC) - (emc)
Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib - Ajay Dhakal, Roby Antony Thomas, Ellis G Levine, Adam Brufsky, Kazuaki Takabe, Matthew G Hanna, Kristopher Attwood,
Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors - ScienceDirect
Everolimus for Treating Hormone Receptor-positive Metastatic Breast Cancer Previously Treated With Cyclin-dependent Kinase 4/6 Inhibitors | Anticancer Research
Progression-free survival, (a) by everolimus dose. Progression-free... | Download Scientific Diagram
1590-Breast metastatic everolimus and exemestane | eviQ
Breast Cancer Everolimus Extends Progression-Free Survival after Failed Hormonal Treatment | Article | NursingCenter
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor – Positive , Human Epidermal Growth Factor Receptor 2 – Negative Metastatic Breast Cancer Resistant to
Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2− Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2 | SpringerLink
Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy | Breast Cancer Research | Full Text
Real World Experience of Long Term Treatment Outcome in Hormone Receptor-positive Metastatic Breast Cancer with or without Everolimus and Exemestane after Prior Aromatase Inhibitor | Asian Pacific Journal of Cancer Care
Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor‐Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy - Cook - 2021 - The Oncologist - Wiley Online Library
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer | NEJM
Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies | npj Breast Cancer
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis | SpringerLink
